In the fight against cancer, it’s boom times for radiopharmaceuticals
STAT | November 8th, 2023
Targeting tumours with novel radiopharmaceuticals
European Pharmaceutical Review | October 19th, 2023
In this exclusive Q&A, Dr Jack Hoppin, CEO, and Dr John Babich, Chief Scientific Officer of Ratio Therapeutics share their perspective on the evolving radiopharmaceutical landscape and why radiopharmaceutical therapeutics have significant potential in oncology.
Developing Best-in-Class Radiopharmaceuticals for Cancer Patients
Rx for Biotech | September 19th, 2023
Our guests for this podcast episode are the co-founders of Ratio Therapeutics, CEO Jack Hoppin, PhD, and Chief Scientific Officer, John Babich, PhD. Ratio Therapeutics’ mission is to develop best-in-class radiopharmaceuticals for the treatment of cancers.
Health Innovators- Dr. Jack Hoppin and Dr. John Babich (follow-up)
Pharmaphorum | August 17th, 2023
The last time we checked in on Ratio Therapeutics co-founders Dr. Jack Hoppin and Dr. John Babich, they were working out of a WeWork co-working space in downtown Boston, just beginning their work with targeted radiotherapeutics and mathematical modelling.
Radiopharmaceuticals for cancer: Making radiation precise
BioPharma Dive | August 15th, 2023
More than a dozen startups are developing drugs that deliver a dose of radiation directly to tumors. Here’s where they stand, and why their progress is worth watching.
Ratio Therapeutics announces first patient dosed in FAP-targeted radiopharmaceutical study
BioPharma Reporter | July 31st, 2023
Boston-based pharma company Ratio Therapeutics has initiated dosing in a phase 1 study evaluating the pharmacokinetics, biodistribution and radiation dosimetry of a novel fibroblast activation protein-alpha (FAP)- targeted radiopharmaceutical, RTX-1363S, for PET imaging in adult healthy volunteers.
Treating Cancer using Targeted Radiotherapeutics with Jack Hoppin and John Babich of Ratio Therapeutics
From Launch to Lab by Qualio | July 26th, 2023
Today we have Dr. Jack Hoppin CEO of Ratio Therapeutics and Dr. John Babich Chief Science Officer of Ratio Therapeutics. The team at Ratio Therapeutics is developing a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancers. They recently opened a 19,000-square-foot headquarters and R&D facility in Boston to continue their exciting innovation.
Ratio: tuning the pharmakokinetics of radiotherapies
BioCentury | June 30th, 2023
The company’s Trillium platform combines the tumor penetration of small molecules with the staying power of mAbs for its actinium-225 therapies.
The dawn of the interim CFO
CFO Dive | May 16th, 2023
With financial leadership coming at a premium, interim CFOs are having their moment in the spotlight.
Ratio Therapeutics unveils new research and development facility
BioPharma Reporter | May 15th, 2023
Boston-based radiopharmaceutical company Ratio Therapeutics has opened a new 19,000 square foot headquarters and R&D facility.
Radiopharmaceuticals on their way to becoming mainstream cancer therapies
BioWorld | April 3rd, 2023
The big idea behind radiopharmaceuticals is taking the hallmarks of two cancer therapies – radiology and chemotherapy – and merging them, and this is what makes the technology a disrupter.
FDA Guiding Industry to Optimize Cancer Drug Dosing in Precision Oncology Era
Precision Oncology News | March 28th, 2023
In releasing a draft guidance earlier this year on dose optimization for cancer therapies, the US Food and Drug Administration is steadily advancing its decades-long campaign to move the industry away from the default use of a maximum-tolerated dosing paradigm in clinical trials and toward a more patient-centered approach.
Ratio To Fine-Tune Radioligand Approach In Cancer With Trillium and Macropa Platforms
SCRIP | March 10th, 2023
The US biotech’s Trillium platform, which has caught the eye of Bayer, could enhance radioligand pharmacokinetics and bioavailability while reducing side effects, enabling the development of both therapeutics and imaging compounds.
#325- Jack Hoppin and John Babich of Ratio Therapeutics
Slice of Healthcare | March 6th, 2023
Our Guests: Jack Hoppin, Chairman & CEO at Ratio Therapeutics and John Babich, Director, President & CSO at Ratio Therapeutics.
Ratio Therapeutics CFO gets due-diligence ready
CFO Dive | February 9th, 2023
The biotech firm’s new CFO wants to make sure the young company is always able to answer questions potential investors may have.
Ratio Therapeutics Raises $20M in Series A Financing
Precision Oncology News | February 2nd, 2023
Ratio Therapeutics on Wednesday announced that it has raised $20 million in a Series A financing round, which it plans to put toward developing its targeted radiotherapeutics for patients with solid tumors.
Tunable Radio Pharmaceuticals? The Founders of Ratio Therapeutics
BioTechIQ Podcast | Janurary 6th, 2023
Throughout many of the discussions on BioTech IQ it is clear that a combination of therapies is likely the answer to treating cancers and other diseases. This is a point well made by the guests on this episode of the show. CEO Jack Hoppin, PhD and Chief Scientific Officer, John Babich PhD are Co-Founders of Ratio Therapeutics. Both bring a successful background in biotech and not only discuss what their organization is doing but lessons they have learned as entrepreneurs in treatment development.
Ratio Therapeutics CDO: “Part of Our Data Team’s Role is Being an Ambassador”
CDO Magazine | December 12th, 2022
Jacob Hesterman, Ratio Therapeutics Chief Data Officer, speaks with Kiran Kanetkar, Pendulum Therapeutics VP of Data and Analytics and CDO Magazine Global Editorial Board Member, in a video interview about the importance of data and analytics in modern drug discovery research, handling data literacy and self-service, and balancing the need for buying and building tools.
Health Innovators- Dr. Jack Hoppin and Dr. John Babich
Pharmaphorum | December 9th, 2022
A few weeks ago, pharmaphorum Editor-in-Chief Jonah Comstock popped in on Ratio Therapeutics co-founders Dr. Jack Hoppin and Dr. John Babich at their WeWork coworking space in downtown Boston for a Health Innovators interview.
Building New Solutions For 2023 In Manufacturing And Supply Chain
Life Science Leader | December 1st, 2022
Manufacturing and scaling the spate of new advanced therapeutics in development will continue to present a challenge in 2023, particularly as key supplies and ingredients remain sluggish to procure. Even so, biopharmaceutical executives contributing to this year’s industry outlook evince a confidence about the solutions they have devised from their respective perches along the value chain. In the following Q&A, 11 executives provide their thoughts on what the future holds for biopharmaceutical manufacturing and supply chain operations, and which issues will have the most impact.
Ratio Therapeutics: Math Meets Medicine in the Design of Radiotherapies
Hopkins Biotech Podcast | November 20th, 2022
Ratio Therapeutics is a Boston-based pharmaceutical company with the mission to accelerate the development of best-in-class targeted radiotherapeutics for the treatment of cancers. By employing a suite of innovative technologies the company is developing innovative and proprietary Pharmacokinetics (PK) Modulation technology for the construction of improved therapeutic agents and transforming oncology treatment paradigms.
Ratio Therapeutics CDO: It’s Rewarding to Ingest Disparate Data in a Structured Way
CDO Magazine | November 1st, 2022
Jacob Hesterman, Ratio Therapeutics Chief Data Officer, speaks with Kiran Kanetkar, Pendulum Therapeutics VP of Data and Analytics and CDO Magazine Global Editorial Board Member, in a video interview about the role of data and analytics in the radiotherapy industry and the approach to managing multidisciplinary data.
Ratio Therapeutics with FAPI and more Audio
The Nuclear Medicine and Molecular Medicine Podcast | October 18th, 2022
We talk with a new company that is harnessing theranostics with ligands we have discussed before.
Targeting and Deploying Optimum Radiopharmaceuticals to Treat Cancer with Jack Hoppin and John Babich Ratio Therapeutics
The Empowered Patient Podcast | September 27th, 2022
Jack Hoppin Ph.D. Chief Executive Officer and John Babich Ph.D., President and Chief Scientific Officer, and Co-Founders of Ratio Therapeutics aim to develop and produce best-in-class radiopharmaceuticals. Harnessing the power of radiation by making it into an injectable drug, Ratio is creating a way to find tumor cells anywhere in the body.
Ratio Therapeutics emerges with $20M financing, taking mathematical approach to radiopharmaceuticals
BioWorld | June 20th, 2022
In the last decade, Bayer AG and Novartis AG have shown that radiopharmaceutical technology can produce marketable drugs, with Xofigo (radium-223 dichloride) and Lutathera (lutetium [177Lu] oxodotreotide), respectively approved for prostate cancer and neuroendocrine tumors.
The Petri Dish: Amylyx, Alnylam net drug approvals
Boston Business Journal | June 16th, 2022
The Massachusetts life sciences industry is rife with companies developing drugs and devices to tackle serious diseases, inking new partnership deals, raising money, expanding facilities and more. Here’s The Petri Dish, a roundup of news that may get overlooked amid the influx of health care happenings.
Ratio Therapeutics Launches to Develop More Target-Specific, Less Toxic Radiopharmaceuticals
Precision Oncology News | June 16th, 2022
Ratio Therapeutics officially launched last week hoping to differentiate itself in the crowded targeted radiopharmaceutical space through technology it believes can home in on tumor tissue and spare toxicity to normal cells better than competitors.